Recap: Cree Q4 Earnings

Shares of Cree (NASDAQ:CREE) fell 5.7% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 27.78% year over year to ($0.23), which beat the estimate of ($0.24).

Shares of Cree (NASDAQ:CREE) fell 5.7% in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 27.78% year over year to ($0.23), which beat the estimate of ($0.24).

Revenue of $145,800,000 declined by 29.12% year over year, which beat the estimate of $145,170,000.

Looking Ahead

Q1 EPS expected to be between ($0.25) and ($0.21).

Q1 revenue expected to be between $144,000,000 and $154,000,000.

Details Of The Call

Date: Aug 17, 2021

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/oqdhenz7

Recent Stock Performance

52-week high: $129.90

Company’s 52-week low was at $56.39

Price action over last quarter: down 16.27%

Company Description

Cree Inc is a United States-based company which is involved in the manufacturing of wide bandgap semiconductor products for power and radio-frequency (RF) applications, lighting-class light-emitting diode (LED) products, and lighting products. It operates in two reportable segments: Wolfspeed and LED products. The Wolfspeed segment’s products consist of silicon carbide and gallium nitride materials, power devices and RF devices based on silicon and wide bandgap semiconductor materials. The LED products segment, which is the key revenue driver, consist of LED chips and LED components. Geographically, the company conducts business in the United States, China, Europe, and other areas.

Total
0
Shares
Related Posts
Read More

Recap: Immunogen Q3 Earnings

Immunogen (NASDAQ:IMGN) reported its Q3 earnings results on Friday, November 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Immunogen missed estimated earnings by 24.0%, reporting an EPS of $-0.31 versus an estimate of $-0.25.

IMGN